Proceeds to fund clinical development of DIAG723, a first-in-class, disease-modifying therapy designed to correct the root cause of hereditary hemorrhagic telangiectasia and pulmonary arterial ...

Hereditary hemorrhagic telangiectasia (HHT) can be fatal. However, it does not affect the average life expectancy of most people. Complications can occur when blood vessels rupture in vital organs.

A clinical trial supported by the National Institutes of Health (NIH) was stopped early after researchers found sufficient evidence that a drug called pomalidomide, which is used to treat bone marrow ...

A clinical trial led by Dr. Keith McCrae of Cleveland Clinic has demonstrated that the cancer drug pomalidomide is safe and effective in treating hereditary hemorrhagic telangiectasia (HHT). The ...

Most people with this condition live a full, typical life, but it can be life threatening if a blood vessel ruptures in an internal organ and bleeds uncontrollably. Osler-Weber-Rendu syndrome, which ...

Atavistik Bio raised $120 million to advance selective allosteric small molecule therapeutics for HHT and MPNs using its proprietary AMPS platform. The AMPS platform integrates computational and ...